Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
131
datasets available to search
ShareScore release 0.9.0
Dataset results
131 results for “immune biomarkers”
Comparative host transcriptomics as a tool to identify candidate biomarkers for immune reactions in leprosy: A meta-analysis study
<p>The dataset consists of R source code for the individual dataset analysis of the studies and their meta-analysis. It also contains supplementary tables and figure.</p>
Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma
<p>Vestibular schwannoma (VS) is an intracranial tumor arising from neoplastic Schwann cells, and typically presenting with hearing loss. The traditional belief that hearing deficit is caused by physical expansion of the VS, compressing the auditory nerve, does not explain the common clinical finding that patients with small tumors can have profound hearing loss, suggesting that tumor-secreted factors could influence hearing ability in VS patients. We conducted profiling of patients' plasma for 66 immune-related factors in patients with sporadic VS (N>170) and identified and validated candidate biomarkers associated with tumor size (S100B) and hearing (MCP-3). We further identified a 9-biomarker panel (TNR-R2, MIF, CD30, MCP-3, IL-2R, BLC, TWEAK, eotaxin, S100B) with outstanding discriminatory ability for VS. These findings revealed possible therapeutic targets for VS, providing a unique diagnostic tool that may predict hearing change and tumor growth in VS patients, and may inform the timing of tumor resection to preserve hearing.</p>
Single Cell Phenotypic Profiling to Identify a Set of Immune Cell Protein Biomarkers for Relapsed and Refractory Diffuse Large B Cell Lymphoma: A Single-Center Study
<p>Diffuse large B-cell lymphoma (DLBCL) is the most common invasive type of non-Hodgkin lymphoma. Cell-of-origin (COO) classification is related to patients’ prognoses. Primary drug resistance in treatment for DLBCL has been observed. The specific serum biomarkers in these patients who suffer from relapsed and refractory (R/R)-DLBCL remains unclear. In the current study, using single-cell RNA sequencing (scRNA-seq) and mass cytometry (CyTOF), we determined and verified immune cell biomarkers at the mRNA and protein levels in single-cell resolution from 18 diagnostic peripheral blood mononuclear cell (PBMC) specimens collected from patients with R/R DLBCL. As controls, five PBMC specimens from healthy volunteers were obtained. We identified a panel of 35 surface marker genes for the features of R/R DLBCL unique cell cluster by scRNA-seq of eight R/R DLBCL patient samples and validated its efficiency in an external cohort consisting of 10 R/R DLBCL patients by CyTOF. The cell clustering and dimension reduction were compared among R/R DLBCL samples in CyTOF Space with COO as well as the C-MYC expression designation. Immune cells from each patient occupied unique regions in the 32-dimensional phenotypic space with no apparent clustering of samples into discrete subtypes. Significant heterogeneity observed in subgroups was mainly attributed to individual differences among samples and not to expression differences in a single, homogeneous immune cell subpopulation. The marker panel showed reliability in labeling R/R DLBCL without any influence from COO stratification and C-MYC expression designation. Furthermore, we compared all the markers between R/R DLBCL and normal samples. A total of 12 biomarkers were significantly overexpressed in R/R DLBCL relative to the normal samples. Therefore, we further optimized the diagnostic biomarker panel of R/R DLBCL comprising CD82, CD55, CD36, CD63, CD59, IKZF1, CD69, CD163, CD14, CD226, CD84, and CD31. In summary, we developed a novel set of biomarkers for the diagnoses of patients with R/R DLBCL. Detections procedures at single-cell resolution provide precise biomarkers which may substantially overcome intertumoral and intratumoral heterogeneity among primary samples. The findings confirmed that each case was unique and may comprise multiple, genetically distinct subclones.</p> <p>Here we uploaded the dataset of CyTOF for external validation. For more detailed information, please contact Dr zheng (zenki_zheng@163.com)</p> <p> </p>
APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population
<p>In post-industrial settings, <i>APOE4</i> is associated with increased cardiovascular and neurological disease risk. However, the majority of human evolutionary history occurred in environments with higher pathogenic diversity and low cardiovascular risk. We hypothesize that in high-pathogen and energy-limited contexts, the <i>APOE4</i> allele confers benefits by reducing innate inflammation when uninfected, while maintaining higher lipid levels that buffer costs of immune activation during infection. Among Tsimane forager-farmers of Bolivia (N=1266), <i>APOE4</i> is associated with 30% lower C-reactive protein, and higher total cholesterol and oxidized-LDL. Blood lipids were either not associated, or negatively associated with inflammatory biomarkers, except for associations of oxidized-LDL and inflammation which were limited to high BMI adults. Further, <i>APOE4</i> carriers maintain higher levels of total and LDL cholesterol at low BMIs. These results suggest the relationship between <i>APOE4</i> and lipids may be beneficial for pathogen-driven immune responses, and unlikely to increase cardiovascular risk in an active subsistence population.</p>
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
ClinicalTrials.gov study NCT03706625. IPD Sharing: YES. Countries: 1. Publications: 0.
A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
ClinicalTrials.gov study NCT04507126. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation
ClinicalTrials.gov study NCT02533180. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Identification of immune-related candidate biomarkers in plasma of patients with sporadic vestibular schwannoma
Open the record for dataset details and reuse information.
APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population
Open the record for dataset details and reuse information.
Biomarkers in Metastatic Castration-Resistant Prostate Cancer for efficiency of Immune Checkpoint Inhibitors
Open the record for dataset details and reuse information.
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients
ClinicalTrials.gov study NCT03486119. IPD Sharing: NO. Countries: 1. Publications: 1.
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT06470997. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Predictive Immune Biomarkers for COVID-19 Pathogenesis
ClinicalTrials.gov study NCT04385108. IPD Sharing: NO. Countries: 1. Publications: 3.
Understanding the Immune System's Role in Tree Nut and Peanut Allergies: Key Biomarkers for Diagnosis and Treatment Monitoring and Treatment Targets
ClinicalTrials.gov study NCT06554691. IPD Sharing: NO. Countries: 1. Publications: 13.
Taxifolin/ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
ClinicalTrials.gov study NCT05190432. IPD Sharing: NO. Countries: 1. Publications: 8.
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
ClinicalTrials.gov study NCT03144947. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Biomarkers For Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT04204434. IPD Sharing: NO. Countries: 1. Publications: 12.
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
ClinicalTrials.gov study NCT03595813. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease
ClinicalTrials.gov study NCT04055831. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes
ClinicalTrials.gov study NCT01747967. IPD Sharing: Not stated. Countries: 1. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.